PET/CT: Basic Principles and Applications in Oncology

Overview of PET/CT

• Presenters: Mabel Djang, HMS III; Gillian Lieberman, MD

• Date: May 2006

• Outline:

  • PET – Basics and Limitations

  • PET/CT - Advantages and Limitations

  • Applications of PET/CT in oncology

  • Summary

Principles of PET

• Definition:

  • PET = Positron Emission Tomography

• Functionality:

  • Offers functional or metabolic assessment of tissue.

  • Utilized in various medical fields:

  • Neurology

  • Cardiology

  • Oncology

Mechanism of PET

• Process:

  1. A biologically important molecule is chosen.

  2. This molecule is labeled with a positron-emitting radiotracer.

  3. The radiotracer is infused into the patient.

  4. Specific tissues absorb the molecule.

  5. A PET scanner detects the location of the molecule in the body as the tracer decays.

Types of Radiotracers

• Examples of Molecules Used for PET:

  • Glucose

  • Thymidine

  • Methionine

  • Estradiol

  • Annexin V

• Production:

  • Positron-emitting radiotracers are produced using a cyclotron.

  • Issues:

  • High cost

  • Practical difficulties in obtaining the labeled molecules.

PET in Oncology

• Key Radiotracer:

  • FDG (18F-fluorodeoxyglucose):

  • A glucose analog.

  • Most frequently used oncologic PET tracer.

  • Non-specific: All glucose-utilizing tissues absorb FDG.

  • Becomes "metabolically trapped" post absorption.

Mechanism of FDG Metabolic Trapping

• Conversion Process:

  • FDG → Absorbed into the cytoplasm through the glucose transporters (GLUT).

  • Converted by hexokinase to FDG-6-P (FDG phosphate).

  • Once converted:

  • Unable to proceed through glycolysis/glycogen formation.

  • FDG-6-P is too polar to diffuse back out of the cell, leading to its "metabolic trapping."

Normal Tissue Uptake of FDG

• Normal Tissues with Notable Uptake:

  • CNS: Brain

  • Cardiovascular: Heart

  • Musculoskeletal: Skeletal muscle

  • Respiratory: Larynx

  • Gastrointestinal (GI) Tract:

  • Stomach

  • Colon

  • Liver

  • Genitourinary (GU) Tract:

  • Kidneys

  • Ureter

  • Bladder

  • Uterus during menstruation

  • Other Organs:

  • Bone marrow

  • Thyroid

  • Spleen

  • Salivary glands

  • Brown fat

Tumor Localization with FDG

• Mechanism of Tumor Detection:

  • Increased FDG uptake in tumors is linked to:

  • Elevated GLUT levels

  • Increased hexokinase activity

  • Enhanced glycolysis rates

  • Identifies areas of hypermetabolism as "hot spots."

  • Utilized in the cancer staging processes for various cancers, including:

  • Lung

  • Colorectal

  • Esophageal

  • Stomach

  • Head and neck

  • Cervical

  • Breast

  • Melanoma

  • Lymphoma

Limitations of PET

• General Limitations:

  • Not all malignancies exhibit FDG avidity, e.g., prostate cancer.

  • Non-malignant tissues can also take up FDG, such as inflammatory tissues (granulomas, post-surgery, arthritis).

  • The resolution of images can be poor.

  • There may be a lack of anatomical landmarks.

Emergence of PET/CT

• Complementary Information:

  • PET provides functional insight but limited anatomical detail.

  • CT offers detailed anatomical and morphologic insights (size, shape, density).

• Challenges in Early Integration:

  • Early attempts at viewing PET and CT images side-by-side proved unsatisfactory due to focus misalignment.

  • Case example of a patient with non-small cell lung cancer illustrates challenge in localization of lesions without fused imaging.

Advances in PET/CT Technology

• Innovative Solutions:

  • Integrated PET and CT in a single machine which allows for simultaneous data collection, optimizing data integration.

  • Dr. David Townsend is credited with this innovation in 2000.

  • 2003: BIDMC became the first facility in Massachusetts to implement PET/CT technology.

Advantages of PET/CT

• Benefits of PET/CT Integration:

  • Improved localization of FDG-avid tissue, encompassing both benign and malignant findings.

  • Enhanced diagnostic accuracy.

  • Reduced scan duration—30 minutes compared to 60 for PET alone—increasing patient comfort during the scanning procedure.

Challenges in PET/CT

• Quality Concerns:

  • CT component of PET/CT scans may not meet diagnostic quality due to being performed at lower radiation doses, which degrades image quality.

  • Current protocols often suffer from effects of patient breathing motion, leading to further image quality issues.

  • The use of oral/IV contrast can result in image artifacts; however, absence of contrast can compromise anatomical clarity.

Application #1: Cancer Staging and Restaging

• Clinical Application Example:

  • In a 58-year-old male with lymphoma, PET/CT before and after chemotherapy demonstrated:

  • Areas of hypermetabolism that regress post-treatment.

  • Areas showing variability in normal uptake indicating no spread of lesions.

Application #2: Assistance with Biopsy

• Clinical Scenario:

  • A presacral mass identified on CT imaging.

  • Initial CT-guided biopsy proved negative.

  • PET/CT revealed that the biopsy bypassed the actual tumor.

  • A repeat biopsy, guided by PET/CT findings, confirmed the presence of the tumor.

Summary of Findings

• Key Principles of PET:

  • Label a biologically significant molecule and trace its location within the body using a PET scanner.

  • Provides crucial metabolic information.

• PET in Oncology:

  • FDG’s characteristic non-specific uptake makes it an effective tumor localizer.

  • Limitations include low resolution and lack of detailed anatomical information.

• PET/CT Integration:

  • Enhances localization of FDG-avid tissues, both benign and malignant.

  • Limitations involve lower quality of CT scans due to various operational factors.

Additional Applications of PET/CT in Oncology

• Other Potential Uses Include:

  • Assisting with biopsies and cancer evaluations among many others.